Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume – What’s Next?

Pharming Group (NASDAQ:PHAR) shares saw an uptick in trading volume on Wednesday . 5,941 shares were traded during mid-day trading, a decline of 5% from the previous session’s volume of 6,240 shares.The stock last traded at $11.68 and had previously closed at $11.95.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Oppenheimer boosted their price target on Pharming Group from $30.00 to $39.00 and gave the stock an “outperform” rating in a research report on Friday, March 14th. HC Wainwright reaffirmed a “buy” rating and set a $37.00 target price on shares of Pharming Group in a research note on Thursday, March 20th.

Pharming Group Trading Up 3.9%

The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41. The company has a fifty day moving average price of $9.57 and a two-hundred day moving average price of $9.13. The firm has a market capitalization of $813.99 million, a price-to-earnings ratio of -46.02 and a beta of 0.02.

Pharming Group (NASDAQ:PHAR) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.03. The firm had revenue of $79.09 million for the quarter, compared to the consensus estimate of $67.74 million. Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. As a group, research analysts forecast that Pharming Group will post -0.2 earnings per share for the current fiscal year.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.